Allos Therapeutics (ALTH) Gets Orphan Drug Designation from U.S. FDA for Pralatrexate
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
